Swiss Blue-chip Index Little Changed; All Eyes on US 'Economic D-Day' Against Iran
Swiss stocks commenced the new trading week little changed, with the Swiss Market Index down 0.07%, as investors await details of the US' vow to unleash an "Economic D-Day" against Iran.In an opinion piece published by the Financial Times over the weekend, US Treasury Secretary Scott Bessent threatened Iran with "the single greatest financial offensive ever marshalled against an adversary," and that any nation conducting financial transactions with the Middle Eastern country would also be isolated. Iranian Foreign Minister Abbas Araghchi dismissed the latest threats as a "desperate" plan and expects it to fail, multiple media outlets including CNBC reported.Back home, the Federal Statistical Office's second estimate showed that Switzerland's hotel sector recorded a 0.6% annual rise in overnight stays for July. Hotel bookings by Swiss nationals rose 4.1%, while those from foreigners declined 2.3%.On the corporate front, Roche (RO.SW) secured approval from the US Food and Drug Administration for its Elecsys pTau217 blood test to identify amyloid pathology associated with Alzheimer's disease in people aged 55 and above who exhibit signs, symptoms or complaints of cognitive decline. The single-biomarker plasma blood test was co-developed with fellow pharmaceutical major Eli Lilly (LLY.SW). Roche's shares closed Monday's session 1.05% lower.Allreal's (ALLN.SW) total sales in the first half decreased to 227.5 million francs from the year-ago 229.8 million francs, while net profit, including revaluation effect, fell 9.6% to 105.6 million francs. Excluding the revaluation effect, net profit stood at 75.6 million francs, up 20.8% year over year. The Swiss real estate developer's stock shed 2.75% at closing."For the financial year 2026, Allreal still expects a higher net operating profit and stable balance sheet figures. In the Real Estate segment, rental income will increase and the vacancy rate will decrease again by the end of the year. In the Development & Realisation segment, the company expects a slight rise in income from the sale of condominiums, a slightly higher construction volume and stable operating expenses," the company said in its earnings release. "However, financing costs will increase slightly, as liabilities with a very favourable rate of interest have matured in the first half year."
